Palmitoyl Pentapeptide-4: What Matrixyl Is and How It Works

At a glance

What is palmitoyl pentapeptide-4?

Palmitoyl pentapeptide-4, often written pal-KTTKS, is a synthetic peptide designed as a topical skincare agent. Its active core, KTTKS, is a five amino acid sequence (lysine-threonine-threonine-lysine-serine) taken from the propeptide of type I collagen. A palmitic acid chain is attached to that core to create the palmitoylated form, pal-KTTKS, which is the version used on skin. It is sold as a cosmetic ingredient under trade names such as Matrixyl, and it is included in serums and moisturizers for skin conditioning, smoothing, and anti-aging purposes.

How does it work?

KTTKS is a fragment released when type I collagen is processed in the skin, and in laboratory studies, it stimulates fibroblasts to produce type I collagen, type III collagen, and fibronectin, the main components of the skin's supportive matrix. Researchers proposed that this fragment acts as a feedback signal, with the released collagen piece prompting cells to make more matrix. The plain KTTKS peptide is not well suited to topical use on its own, so a palmitic acid group is attached to create pal-KTTKS, the form developed as a topical agent to stimulate collagen production for an anti-wrinkle benefit. Applied to the skin, it is used to support the appearance of firmer skin and reduce the look of fine lines and wrinkles.

Is palmitoyl pentapeptide-4 FDA-approved?

No, and it does not need to be. The FDA does not approve cosmetics or most cosmetic ingredients before they go on the market. Cosmetics are regulated and must be safe when used as directed and properly labeled, but there is no pre-market approval step the way there is for drugs, so no anti-aging peptide in a serum is "FDA-approved." The line that actually matters for an ingredient like this is the difference between a cosmetic and a drug. A product is a cosmetic when it is intended to improve appearance, but if it claims to change the structure or function of the skin, the FDA can regulate it as an unapproved drug. This is why skincare claims are usually written around the appearance of the skin rather than a promised physiological change.

What is it used for?

Palmitoyl pentapeptide-4 is used almost entirely in topical anti-aging products, where it is included for skin conditioning, smoothing, and soothing. In its main clinical study, it was tested for improving the appearance of fine lines and wrinkles in photoaged facial skin.

What does the research show?

The main controlled evidence is a trial, and the rationale for its effect traces to earlier laboratory work.

The evidence base is real but limited:

• The key trial was conducted by researchers at Procter & Gamble.
• Sample sizes are small.
• There is little large, independent, or long-term data.

That supports a modest cosmetic benefit rather than a dramatic effect, which is why it sits at Moderate research on the evidence scale.

What are the side effects?

In its clinical study, pal-KTTKS was well tolerated by the skin. As with any skincare ingredient, some people can still experience mild redness, irritation, or an allergic reaction, so a patch test before regular use is sensible. Because the peptide is applied to the skin rather than injected, the safety considerations are those of a typical cosmetic ingredient.

Evidence strength

Moderate research: It has human trial evidence, including a 2005 double-blind, placebo-controlled study, but that evidence is limited: the trials are small, largely manufacturer-associated, and have not been replicated in large independent studies or pooled into a meta-analysis.

Sources: the 2005 double-blind, placebo-controlled trial of pal-KTTKS in the International Journal of Cosmetic Science (DOI: 10.1111/j.1467-2494.2005.00261.x); the 1993 laboratory study of the KTTKS collagen fragment (indexed on PubMed); and cosmetic ingredient references. This document is educational and does not constitute medical advice or a treatment claim.